TARS Stock — Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. (TARS)

Updated October 16, 2026.

TARS is a Stock. Total return is 230.8% over the past 6 years, 92.5 points ahead of SPY at 138.3%.

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company developing and selling therapeutic treatments for eye care conditions. The company markets XDEMVY, an FDA-approved solution for demodex blepharitis, and is advancing a pipeline that includes candidates for ocular rosacea, Lyme disease prevention, and community malaria reduction, primarily using the lotilaner active pharmaceutical ingredient. As an operating biopharmaceutical company without an established dividend program, it is oriented toward investors seeking growth potential rather than current income.

TARS performance versus SPY

Price and return data through 2026-10-16.

Total return is 230.8% over the past 6 years, 92.5 points ahead of SPY at 138.3%. Over the past year its total return — price change plus distributions reinvested — is -9.2%. Its deepest 1-year drawdown was 32.0%.

TARS key facts

Asset type

Stock

Asset class

Equity

Inception date

10/16/2020

Distribution frequency

None

Last close

$68.07 (as of 2026-10-16)

Market cap

$3,185,110,202

Average volume

2432250.0

Beta

0.541

Payout ratio

0.0%

Forward P/E

68.0272

EPS

$-1.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TARS risks and drawbacks

The deepest 1-year drawdown on record here is 32.0%.

Who may consider TARS — and who may not

It is a weaker fit for investors who need monthly cash flow (TARS does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on TARS

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions